Clinical pharmacokinetics of ondansetron. A review

Journal of Pharmacy and Pharmacology

Volumn 48, Issue 8, 1996, Pages 774-781

  Simpson, Karen H ^a   Hicks, Fiona M ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANTIEMETIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; DIAZEPAM; METOCLOPRAMIDE; ONDANSETRON; OPIATE; PYRIDOSTIGMINE; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR;

ADOLESCENT; ADRENERGIC SYSTEM; ADULT; ALCOHOL CONSUMPTION; ANXIETY NEUROSIS; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM; CHILD; CHOLINERGIC SYSTEM; CONSTIPATION; CONTROLLED STUDY; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ENTEROCHROMAFFIN CELL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL MUCOSA; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTESTINE INNERVATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LIVER DISEASE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRESCHOOL CHILD; RECTAL DRUG ADMINISTRATION; REVIEW; SCHOOL CHILD; SENSORY NERVE; SMOKING; SUBCUTANEOUS DRUG ADMINISTRATION; VAGUS NERVE; VOMITING;

EID: 0029841161     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.1996.tb03973.x     Document Type: Review

References (56)

1. Adler, M., Marschner, N., Janicke, F. (1991) Antiemetic efficacy of ondansetron in long term therapy. Eur. J. Cancer 27 (Suppl. 1): S27
2. Amantea, M. A., Yarboro, C., Forrest, A., Pucino, F., Klippel, J. H. (1993) Population pharmacokinetics of intravenous and oral ondan-setron in patients with systemic lupus erythematosus (SLE). J. Clin. Pharmacol. 33: 1004
3. Ashforth, E. I. L., Palmer, J. L., Bye, A., Bedding, A. (1994) The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolizers of debrisoquine. Br. J. Clin. Pharmacol. 37: 389-391
4. Baber, N., Palmer, J. L., Frazer, N. M., Pritchard, J. F. (1992) Clinical pharmacology of ondansetron in postoperative nausea and vomiting. Eur. J. Anaesthesial. 9 (Suppl. 6): 11-18
5. Blackwell, C. P., Harding, S. M. (1989) The clinical pharmacology of ondansetron. Eur. J. Clin. Oncol. 25 (Suppl. 1): S21-S24
6. Blake, J. C., Palmer, J. L., Minton, N. A., Burroughs, A. K. (1993) The pharmacokinetics of ondansetron in patients with hepatic impairment. Br. J. Clin. Pharmacol. 35: 441-443
7. Brouwer, R., Jarrett, J. L., Nystrom, D. K.., Anderson, D. L., Brown, K., Farrish, H. H. (1992) Efficacy of ondansetron in male mongrel dogs and effects of the pharmacokinetics of cisplatin. Pharm. Res. 9 (Suppl.): 267
8. Bryson, J. C., Pritchard, J. F., Shurin, S., Kernodle, A. E., Blumer, J. L. (1991) Efficacy, pharmacokinetics and safety of ondansetron in paediatric chemotherapy patients. Am. Soc. Clin. Pharmacol. Ther. 49: 161
9. 3 receptors. Br. J. Pharmacol. 94: 397-412
10. 3 receptor antagonist ondansetron. FASEB J. 7: A699
11. Claybon, L. (1994) Single dose intravenous ondansetron for the 24 hour treatment of postoperative nausea and vomiting. Anaesthesia 49 (Suppl.): 24-29
12. Colthup, P. V., Palmer, J. I. (1989) The determination in plasma and pharmacokinetics of ondansetron. Eur. J. Clin. Oncol. 25 (Suppl. 1): S71-S74
13. Colthup, P. V., Felgate, C. C., Palmer, J. L., Scully, N. L. (1991) Determination of ondansetron in plasma and its pharmacokinetics in the young and elderly. J. Pharm. Sci. 80: 868-871
14. 3 receptor antagonist GR 38032F on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br. J. Pharmacol. 92: 881-894
15. Costall, B., Naylor, R. J., Tyers, M. (1990) The psychopharmacology of 5-HT receptors. Pharmacol. Ther. 47: 181-190
16. Dobrow, R. B., Coppock, M. A., Hosenpud, J. R. (1991) Extrapyramidal reaction caused by ondansetron. J. Clin. Oncol. 9: 1921
17. Figg, W. D., Dukes, G. E., Pritehard, J. F., Hak, L. J., Songer, S. S., Lesesne, H. R., Kao, C. F., Hermann, D. J., Powell, J. R. (1992) Ondansetron pharmacokinetics in chronic liver disease. Clin. Pharmacol. Ther. 51: 171
18. Fischer, V., Vickers, A. E. M., Heitz, F., Mahadevan, S., Baldeck, J. P., Minery, P., Tynes, R. (1994) The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab. Dispos. 22: 269
19. Frazer, N. M., Palmer, J. L. (1992) Tolerability and pharmacokinetics of intramuscular ondansetron 4 mg. Anesthesiology 77 (Suppl. 3A): A439
20. Gan, L. S., Hsyu, P. H., Pritchard, J. F., Thakka, D. (1993) Mechanism of intestinal absorption of ranitidine and ondansetron: transport across caco-2 cell monolayers. Pharm. Res. 10: 1722-1725
21. Garcia-del-Muro, X., Cardenal, F., Ferrer, P. (1993) Extrapyramidal reaction associated with ondansetron. Eur. J. Cancer 29A: 288
22. Grunberg, S. M., Stevenson, L. L., Russell, C. A., McDermed, J. E. (1989) Dose ranging phase 1 study of the serotonin antagonist GR38032F for prevention of cisplatin induced nausea and vomiting. J. Clin. Oncol. 7: 1137-1141
23. Grunberg, S. M., Groshen, S., Robinson, D. C., Stevenson, L. L., Sanderson, P. E. (1990) Correlation of antiemetic efficacy and plasma levels of ondansetron. Eur. J. Cancer 26: 879-882
24. Halperin, J. R., Murphy, B. (1992) Extrapyramidal reaction to ondansetron. Cancer 69: 1275
25. Hsyu, P. H., Haig, P., Bozigian, J., Pritchard, J. F., Kernodle, A., Panella, J., Hansen, L. A., Griffin, R. H. (1991) Effect of chemotherapy on the pharmacokinetics of oral ondansetron. Pharm. Res. 8 (Suppl.): 257
26. Hsyu, P. H., Pritchard, J. F., Bozigian, H. P., Gooding, A. E., Griffin, R. H., Mitchell, R., Bjurstrom, T., Panella, T. L., Huang, T., Hansen, L. A. (1994a) Oral ondansetron pharmacokinetics: the effect of chemotherapy. J. Clin. Pharmacol. 34: 767-773
27. Hsyu, P. H., Pritchard, J. F., Bozigian, H. P., Lloyd, T. C., Griffin, R. H., Shamburek, R., Krishna, G., Barr, W. H. (1994b) Comparison of the pharmacokinetics of ondansetron solution (8 mg) when administered intravenously, orally, to the colon and to the rectum. Pharm. Res. 11: 156-159
28. Johnson, B. A., Rue, J., Cowen, P. J. (1993) Ondansetron and alcohol pharmacokinetics. Psychopharmacology 112: 145
29. 3 receptor antagonist. Br. J. Pharmacol. 93: 985-993
30. Kanarek, B. B., Curnow, R., Palmer, J., Cook, S. F. (1992) Ondansetron: confusing documentation surrounding an extrapyramidal reaction. J. Clin. Oncol. 10: 506-507
31. Kennard, D., Butcher, M., Palmer, J., Beranek, P., Brown, G. W. (1991) The antiemetic efficacy, pharmacokinetics and safety of ondansetron in the elderly receiving cancer chemotherapy or radiotherapy. Eur. J. Cancer 27 (Suppl. 1): S27
32. 3 receptors. Med. Res. Rev. 10: 441-475
33. Lazarus, H. M., Bryson, J. C., Lemon, E., Pritchard, J. F., Blumer, J. (1990) Antiemetic efficacy and pharmacokinetic analyses of the serotonin antagonist ondansetron (GR 38032F) during multiple day chemotherapy with cisplatin prior to autologous bone marrow transplantation. J. Natl. Cancer Inst. 82: 1776-1178
34. Lerman, J., Sphar-Schopfer, I. A., Sikich, N. (1993) Pharmacokinetics of intravenous ondansetron in healthy children. Can. J. Anaesthesiol. 40: A24
35. Mackinnon, J. W. M., Coll, D. T. (1989) The chemistry of ondansetron. Eur. J. Cancer Clin. Oncol. 25 (Suppl. 1): S61-S70
36. McQueen, K. D., Milton, J. D. (1994) Multicentre post marketing surveillance of ondansetron therapy in paediatric patients. Ann. Pharmacother. 23: 85-92
37. Mitchell, K. E., Popkin, M. K., Trick, W., Vercelotti, G. (1994) Psychiatric complications associated with ondansetron. Psychosomatics 35: 161-163
38. Mizoguchi, H., Suzuki, T., Mizawa, M. (1993) Effects of serotonergic anxiolytics on physical dependence on diazepam in mice. Neurosci. Lett. 160: 41-44
39. Naylor, R. J., Rudd, J. A. (1992) Pharmacology of ondansetron. Eur. J. Anaesthesiol. 9 (Suppl. 6): 3-15
40. Palmer, J. L., Frazer, N. M., Keene, O. N., Baber, N. S. (1993) Tolerability and pharmacokinetics of intramuscular ondansetron 4 mg. Am. Soc. Clin. Pharmacol. Ther. 53: 209-215
41. Parr, M. D., McIntyre, W. J., Henderson, L. M., MacDonald, J. S., Chandler, M. H. H. (1992) Pharmacokinetics of ondansetron in patients receiving cisplatin therapy. Clin. Pharm. 11: 1026-1029
42. Pearlman, M. H. (1994) Single dose IV ondansetron in the prevention of postoperative nausea and vomiting. Anaesthesia 49 (Suppl.): 11-20
43. Pritchard, J. F. (1992) Ondansetron metabolism and pharmacokinetics. Semin. Oncol. 19 (Suppl. 10): 9-15
44. Pritchard, J. F., Powell, J. R. (1991) Circadian variations in the pharmacokinetics of ondansetron. Clin. Pharmacol. Ther. 49: 129
45. Pritchard, J. F., Bryson, J. C., Kernodle, A. E., Benedetti, T. L., Powell, J. K. (1992) Age and gender effects on ondansetron pharmacokinetics: evaluation of healthy aged volunteers. Clin. Pharmacol. Ther. 51: 51-55
46. Pritchard, J. F., Wells, C. D. (1992) Relationship between ondansetron systemic exposure and antiemetic efficacy and safety in patients receiving cisplatin. Pharmacology 45: 188-194
47. 3 receptor binding sites in human dorsal vagal complex. Eur. J. Pharmacol. 174: 127-130
48. Rust, M., Cohen, L. A. (1994) Single dose ondansetron in the prevention of postoperative nausea and emesis. Anaesthesia 49 (Suppl.): 16-20
49. Saynor, D. A., Dixon, C. M. (1989) The metabolism of ondansetron. Eur. J. Clin. Oncol. 25 (Suppl. 1): S75-S77
50. Simpson, K. H., Murphy, P., Colthup, P. V., Whelan, P. (1992) Concentration of ondansetron in cerebrospinal fluid following oral dosing in volunteers. Psychopharmacology 109: 497-498
51. Sommers, D. K., van Wyk, M., Snyman, J. R., Moncrieff, J. (1994) Influence of granisetron, ondansetron and metoclopramide on gastric emptying, oro-caecal transit time and theophylline absorption from a sustained release formulation. Med. Sci. Res. 22: 329-331
52. Spitzer, T. R., Bryson, J. C., Cirenzo, E., Foebler, R., Wallerstadt, M., Stout, M., Kunka, R. L., Plagge, P. B., Dubois, A. (1994) Randomized double blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. J. Clin. Oncol. 12: 2432-2438
53. Stevens, R. F. (1991) The role of ondansetron in paediatric patients: a review of three studies. Eur. J. Cancer 27 (Suppl. 1): S20-S22
54. Talley, N. J., Philips, S. F., Haddad, A., Miller, L. J., Twomey, C., Zinsmeister, A. R., MacCarty, R. C., Giociola, A. (1990) GR38032F (ondansetron), a selective 5-HT receptor antagonist, slows colonic transit in healthy man. Dig. Dis. Sci. 35: 477-480
55. Tyers, M. (1992) Pharmacology and preclinical antiemetic properties of ondansetron. Semin. Oncol. 19 (Suppl 10): 1-8
56. White, A., Corn, T. H., Feetham, C., Faulconbridge, C. (1991) Ondansetron in the treatment of schizophrenia. Lancet 337: 1173